Inflation Reduction Act Likely to Shape Specialty Prescribing Decisions in 2025, According to Spherix Global Insights
Spherix Global Insights Announces New Study on Impact of Inflation Reduction Act (IRA) on Specialty Practices and Key Insights for Biopharmaceutical Companies in 2025. Exton, PA., December 10, 2024 – In 2022, the U.S. Congress enacted the Inflation Reduction Act (IRA), a landmark piece of legislation aimed at addressing various national priorities, including the reduction […]
‘The most challenging disease’: Misdiagnoses, unmet needs abound in systemic sclerosis
Systemic sclerosis is the most challenging diagnosis to make among rheumatic and autoimmune conditions, according to 91% of respondents in a market analysis from Spherix Global Insights. “I agree with the survey responses in that the rheumatologists highlighted systemic sclerosis as the most challenging diagnosis and the most challenging disease to manage in practice,” Dinesh Khanna, MD, MSc, professor […]
Survey: U.S. Derms and Rheums Report “Extremely High” Unmet Need for New Treatments in DM
More than half of dermatomyositis patients are not optimally managed, according to a survey of 102 U.S. rheumatologists and dermatologists by Spherix Global Insights. Currently, the standard of care predominantly involves corticosteroids, topical therapies, traditional disease-modifying anti-rheumatic drugs (tDMARDs), and, in more severe or refractory cases, intravenous immunoglobulin (IVIg) or off-label biologics, underscoring the growing […]
US Rheumatologists and Dermatologists Report Over Half of their Dermatomyositis Patients Not Optimally Managed, According to Spherix Global Insights
Although CSL Behring’s Hizentra (IgPro20) is touted as akey pipeline agent to watch, rheumatologists currently prefer AstraZeneca’sSaphnelo (anifrolumab), while dermatologists favor Priovant Therapeutics’brepocitinib. Exton, PA, October 18, 2024 – Dermatomyositis (DM) is a rare inflammatory disease characterized by muscle weakness and a distinctive skin rash. Currently, the standard of care predominantly involves corticosteroids, topical therapies, […]
Roche/Genentech’s Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results
Following positive topline results from the Phase III REGENCY trial, Gazyva is positioned to compete with Benlysta and Lupkynis in the lupus nephritis treatment landscape, pending approval. EXTON, PA., October 10, 2024 – While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a serious […]
US Rheumatologists Identify BAFF-R Inhibitors as the Most Promising Treatment Approach for Sjögren’s Disease, According to Spherix Global Insights
Despite keen interest in BAFF-R inhibition, rheumatologists favor BMS’ Sotyktu (deucravacitinib) as the leading therapy in development for Sjögren’s. EXTON, PA., October 02, 2024 — Sjögren’s disease is a systemic autoimmune rheumatic condition that can profoundly affect a patient’s overall functioning. Common symptoms include significant dryness, particularly in the eyes and mouth, along with severe […]
Despite Projections of a 2024 Adalimumab Biosimilar Boom, Humira Remains Dominant for Now, According to Spherix Global Insights
US gastroenterologists more in favor of biosimilars than rheumatology and dermatology counterparts. EXTON, PA., September 23, 2024 — Spherix Global Insights compiled data from their RealTime Dynamix™ services in Crohn’s Disease, Rheumatoid Arthritis, and Psoriasis, fielded in late April 2024 (n=104 gastroenterologists, 103 rheumatologists, and 106 dermatologists), to provide an updated perspective on adalimumab biosimilar […]
Lupus landscape ‘poised for evolution’ as US doctors eagerly await new entrants
Biogen’s litifilimab “stands out as an especially strong competitor” to Benlysta and Saphnelo, according to Spherix Global Insights analysts. New biologics such as GSK’s Benlysta and AstraZeneca’s Saphnelo, along with off-label drugs, have been the mainstay for systemic lupus erythematosus (SLE) treatment for many years. However, the landscape may be about to change with the […]
US Rheumatologists Believe Biogen’s Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data
Despite favorable views on litifilimab, AbbVie’s Rinvoqand BMS’ Sotyktu capture the most prescriber interest for approval, accordingto Spherix Global Insights. EXTON, PA., September 12, 2024 — The systemic lupus erythematosus (SLE) advanced treatment landscape is poised for evolution, with multiple new therapies in development to treat this debilitating and chronic disease. While Biogen’s litifilimab has […]
Rheumatologists’ Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
As treatment strategies evolve, rheumatologists are refining SLE care with targeted biologics, driving a paradigm shift in lupus management, according to Spherix Global Insights. EXTON, PA., June 13, 2024 – Since 2021, the treatment options for systemic lupus erythematosus (SLE) and lupus nephritis (LN) have expanded with the approval of AstraZeneca’s Saphnelo (anifrolumab) for SLE, […]
